Rocket Pharmaceuticals (STU:9IP1) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9IP1 Rocket Pharmaceuticals Inc STU:9IP1
39 GF Score
Price €3.00
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

STU:9IP1
39GF Score
Rocket Pharmaceuticals Inc STU:9IP1
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Business Description

Other Exchanges RCKT:USA
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
39GF Score

Get the complete analysis for STU:9IP1

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.00
Price